Watch IMMX. Know when insiders buy.
One email the day a filing lands. Free.
IMMX
Immix Biopharma, Inc.
12.72
+0.80 +6.71%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
69
PASS · shorts 69
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $910MP/E —DIV YIELD —FCF YIELD -4.30%REV TTM —NET INCOME −$39.9MNET CASH —52W 2.04 – 14.47SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$12.5M | −$11.6M | — | -0.18 | −$11.7M | $21K | −$11.8M | Aug 7 |
| Q1 2026 · Mar 31 | — | — | — | −$10.8M | −$10.1M | — | -0.18 | −$9.8M | $32K | −$9.9M | Aug 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$10.9M | −$10.6M | — | -0.28 | −$11M | $165K | −$11.2M | Aug 7 |
| Q3 2025 · Sep 30 | — | — | — | −$7.7M | −$7.6M | — | -0.24 | −$5.9M | $372K | −$6.3M | Nov 7 |
| Q2 2025 · Jun 30 | — | — | — | −$6.7M | −$6.6M | — | -0.22 | −$5.3M | $128K | −$5.4M | Aug 7 |
| Q1 2025 · Mar 31 | — | — | — | −$4.7M | −$4.5M | — | -0.15 | −$1.7M | $68K | −$1.8M | Aug 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$5M | −$4.8M | — | -0.16 | −$1.5M | $507K | −$2M | Mar 27 |
| Q3 2024 · Sep 30 | — | — | — | −$7.4M | −$7.1M | — | -0.24 | −$4M | $272K | −$4.3M | Nov 7 |
| Q2 2024 · Jun 30 | — | — | — | −$4.7M | −$4.4M | — | -0.15 | −$5.3M | $97K | −$5.4M | Aug 8 |
| Q1 2024 · Mar 31 | — | — | — | −$5.6M | −$5.3M | — | -0.22 | −$3.8M | $302K | −$4.1M | May 8 |
| Q4 2023 · Dec 31derived | — | — | — | −$5.4M | −$5.1M | — | -0.24 | −$2.7M | $13K | −$2.7M | Mar 25 |
| Q3 2023 · Sep 30 | — | — | — | −$4.5M | −$4.3M | — | -0.23 | −$3.1M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$30M | −$29.4M | — | -0.89 | −$23.9M | $733K | −$24.7M | — | — |
| FY2024 · to Dec 31 | — | — | −$22.7M | −$21.6M | — | -0.76 | −$14.6M | $1.2M | −$15.8M | — | — |
| FY2023 · to Dec 31 | — | — | −$16.1M | −$15.4M | — | -0.89 | −$11.4M | $52K | −$11.4M | — | — |
| FY2022 · to Dec 31 | — | — | −$8.2M | −$8.2M | — | -0.59 | −$7.4M | — | — | $100K | — |
| FY2021 · to Dec 31 | — | — | −$1.4M | −$24.4M | — | -6.64 | −$1.6M | $802 | −$1.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$454K | −$1.1M | — | -0.34 | −$405K | — | — | — | — |
Every number comes from Immix Biopharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.